Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg ...

On Tuesday, NICE - which recommends medicines for use on the NHS - recommended a daily pill for people with the disease, ...

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

For patients who are unable to tolerate or who refuse surgery, endoscopic biliary sphincterotomy or treatment with ursodeoxycholic acid are reasonable alternatives. Additional controlled ...

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The ...

Patients with symptoms of easy fatigability, myalgia, or arthralgia; manifestations of jaundice; and laboratory abnormalities that reflect severe liver inflammation have absolute indications for ...

Trade named Iqirvo, the drug is recommended in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This ...

The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in adults, either in combination with ursodeoxycholic acid (UDCA) or as monotherapy for those ...

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid ...

either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated ...

who do not respond or are intolerant to standard first-line therapy with ursodeoxycholic acid (UDCA), with a decision due by 14th August. Out of 99 patients from seladelpar studies who have been ...